GlassScriptPhysician profile
Laura M Lundgren
NPI 1427101146
$413.34
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $167 · 2021: $20.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $102.06 | 2019-2020 | |
| Kaleo, INC. | $72.88 | 2019 | |
| Tris Pharma INC | $55.65 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $42.52 | 2020-2021 | |
| Sarepta Therapeutics, INC. | $21.11 | 2019 | |
| Sobi, INC | $18.98 | 2020 | |
| Pfizer INC. | $18.40 | 2020 | |
| Adlon Therapeutics L.P. | $17.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.64 | 2020 | |
| Mylan Pharmaceuticals INC. | $17.22 | 2019 | |
| Sanofi Pasteur INC. | $15.09 | 2019 | |
| Mission Pharmacal Company | $13.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Lundgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.